TY - JOUR
T1 - Monkeypox infection elicits strong antibody and B cell response against A35R and H3L antigens
AU - Yefet, Ron
AU - Friedel, Nadav
AU - Tamir, Hadas
AU - Polonsky, Ksenia
AU - Mor, Michael
AU - Cherry-Mimran, Lilach
AU - Taleb, Eyal
AU - Hagin, David
AU - Sprecher, Eli
AU - Israely, Tomer
AU - Freund, Natalia T.
N1 - Funding Information: We thank all the donors. We thank the members of the Freund Lab for fruitful discussions. We thank Dr Ohad Mazor from the Israel Institute for Biological Research for his support. K.P.’s research is supported in part by a fellowship from the Edmond J. Safra Center for Bioinformatics at Tel Aviv University . We thank Vice President of Research and Development of Tel Aviv University for funding. We thank Mr. Eli Gelman and Prof. Ariel Porat for their support. Images for graphical abstract were created using BioRender. Funding Information: We thank all the donors. We thank the members of the Freund Lab for fruitful discussions. We thank Dr Ohad Mazor from the Israel Institute for Biological Research for his support. K.P.’s research is supported in part by a fellowship from the Edmond J. Safra Center for Bioinformatics at Tel Aviv University. We thank Vice President of Research and Development of Tel Aviv University for funding. We thank Mr. Eli Gelman and Prof. Ariel Porat for their support. Images for graphical abstract were created using BioRender. R.Y. planned and performed the experiments, analyzed data, prepared the figures, and wrote the manuscript together with N.T.F. N.F. conducted the patient follow up and recruited the donors and collected the samples with the help of E.T. H.T. and T.I. carried out all the neutralization studies, analyzed viral inhibition data with the help of LCM, as well as critically reviewed the data and the manuscript. M.M. helped with protein production and cloning. K.P. performed the AlphaFold predictions. D.H. and E.S. wrote and submitted the ethics protocols, helped design the study and oversaw donor enrolment into the study. N.T.F. planned and supervised the experiments, wrote the ethical protocols, analyzed the data and wrote the manuscript. The authors declare no conflict of interest. Publisher Copyright: © 2023 The Author(s)
PY - 2023/2/17
Y1 - 2023/2/17
N2 - Monkeypox virus (MPXV) resides in two forms; mature and enveloped, and depending on it, distinct proteins are displayed on the viral surface. Here, we expressed two MPXV antigens from the mature, and one from the enveloped form, and tested their reactivity to sera of 11 MPXV recoverees while comparing to sera from recently and past vaccinated individuals. 8 out of 11 recoverees exhibited detectable neutralization levels against Vaccinia Lister. Sera from all recoverees bound strongly to A35R and H3L antigens. Moreover, the responses to A35R were significantly higher within the recoverees compared to both recently and past vaccinated donors. Lastly, A35R- and H3L-specific IgG+ B cells ranging from 0.03-0.46% and 0.11–0.36%, respectively, were detected in all recoverees (A35R), and in 9 out of 11 recoverees (H3L). Therefore, A35R and H3L represent MPXV immune targets and could be used in a heat-inactivated serological ELISA for the identification of recent MPXV infection.
AB - Monkeypox virus (MPXV) resides in two forms; mature and enveloped, and depending on it, distinct proteins are displayed on the viral surface. Here, we expressed two MPXV antigens from the mature, and one from the enveloped form, and tested their reactivity to sera of 11 MPXV recoverees while comparing to sera from recently and past vaccinated individuals. 8 out of 11 recoverees exhibited detectable neutralization levels against Vaccinia Lister. Sera from all recoverees bound strongly to A35R and H3L antigens. Moreover, the responses to A35R were significantly higher within the recoverees compared to both recently and past vaccinated donors. Lastly, A35R- and H3L-specific IgG+ B cells ranging from 0.03-0.46% and 0.11–0.36%, respectively, were detected in all recoverees (A35R), and in 9 out of 11 recoverees (H3L). Therefore, A35R and H3L represent MPXV immune targets and could be used in a heat-inactivated serological ELISA for the identification of recent MPXV infection.
KW - Immunological methods
KW - Immunology
KW - Virology
UR - https://www.scopus.com/pages/publications/85146845692
U2 - 10.1016/j.isci.2023.105957
DO - 10.1016/j.isci.2023.105957
M3 - Article
C2 - 36687315
SN - 2589-0042
VL - 26
SP - 105957
JO - iScience
JF - iScience
IS - 2
M1 - 105957
ER -